Corey Douglas Code - 11 Dec 2025 Form 4 Insider Report for Ovintiv Inc. (OVV)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
12 Dec 2025, 20:53:53 UTC
Prior SEC filing
01 Oct 2025
Next SEC filing
05 Jan 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/Dawna Gibb, by Power of Attorney

Key filing fact

Corey Douglas Code filed Form 4 for Ovintiv Inc. (OVV) on 12 Dec 2025.

Key facts

  • This page summarizes Corey Douglas Code's Form 4 filing for Ovintiv Inc. (OVV).
  • 6 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 12 Dec 2025, 20:53.

Change

  • Previous filing in this sequence was filed on 01 Oct 2025.
  • Current net transaction value: -$300,474.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001776159 Primary reporting owner

Code Corey Douglas

Relationship
EVP & CFO
Address
C/O 370 17TH STREET, SUITE 1700, DENVER
Signature
/s/Dawna Gibb, by Power of Attorney
Signature date
12 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OVV transaction

Common Stock

Options Exercise

Transaction value
$242,306
Shares
+6,997
Change %
+4.9%
Price
$34.63
Shares after
149,386
Date
11 Dec 2025
Ownership
Direct
Footnotes
F2
OVV transaction

Common Stock

Disposed to Issuer

Transaction value
$291,915
Shares
-6,997
Change %
-4.7%
Price
$41.72
Shares after
142,389
Date
11 Dec 2025
Ownership
Direct
Footnotes
F4
OVV transaction

Common Stock

Options Exercise

Transaction value
$910,745
Shares
+27,843
Change %
+20%
Price
$32.71
Shares after
170,232
Date
11 Dec 2025
Ownership
Direct
Footnotes
F3
OVV transaction

Common Stock

Disposed to Issuer

Transaction value
$1,161,610
Shares
-27,843
Change %
-16%
Price
$41.72
Shares after
142,389
Date
11 Dec 2025
Ownership
Direct
Footnotes
F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OVV transaction Derivative

Stock Option

Options Exercise

Transaction value
$0
Shares
-6,997
Change %
-100%
Price
$0.000000
Shares after
0
Date
11 Dec 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,997
Exercise price
$34.63
Footnotes
F1, F2
OVV transaction Derivative

Stock Option

Options Exercise

Transaction value
$0
Shares
-27,843
Change %
-100%
Price
$0.000000
Shares after
0
Date
11 Dec 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
27,843
Exercise price
$32.71
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Option to buy Ovintiv Inc. common stock with tandem stock appreciation right. Each Stock Option is the economic equivalent of one share of Ovintiv Inc. common stock.

Footnote F2

The Stock Options were awarded in Canadian dollars at a price of CAD$47.70 per Stock Option. The price has been converted to U.S. dollars using the Bank of Canada exchange rate on the transaction date.

Footnote F3

The Stock Options were awarded in Canadian dollars at a price of CAD$45.05 per Stock Option. The price has been converted to U.S. dollars using the Bank of Canada exchange rate on the transaction date.

Footnote F4

The shares of Ovintiv Inc. common stock were sold in Canadian dollars at a price of CAD$57.46 per share. The price has been converted to U.S. dollars using the Bank of Canada exchange rate on the transaction date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .